Definitions Primary amenorrheaFailure of menarche to occur when expected in relation to the onset of pubertal development. • No menarche by age 16 years with signs of pubertal development. • No onset of pubertal development by age 14 years. Secondary amenorrhea • Absence of menstruation for 3 or more months in a perviously mentruating women of reproductive age.
CLINICAL GUIDELINES FOR EVALUATION AND MANAGEMENT OF AMENORRHEA
Dr. JEHAD YOUSEF
FICS, FRCOG
AMMAN-JORDAN
Definitions
Primary amenorrhea
Failure of menarche to occur when expected in relation to the onset of pubertal development.
• No menarche by age 16 years with signs of pubertal development.
• No onset of pubertal development by age 14 years.
Secondary amenorrhea
• Absence of menstruation for 3 or more months in a perviously mentruating women of reproductive age.
Pathophysiology of Amenorrhea
• Inadequate hormonal stimulation of the endomerium
"Anovulatory amenorrhea"
– Euestrogenic
– Hypoestrogenic
• Inability of endometrium to respond ot hormones
"Ovulatory amenorrhea"
– Uterine absence – Utero-vaginal agenesis
– XY-Females (e.g. T.F.S)
– Damaged endometrium (e.g. Asherman's syndrome)
AMENORRHOEA
AN APPROACH FOR DIAGNOSIS
• HISTORY
• PHYSICAL EXAMINATION
• ULTRASOUND EXAMINATION
Exclude Pregnancy
Exclude Cryptomenorrhea
Cryptomenorrhea
Outflow obstruction to mentrual blood
– Imperforate hymen
– Transverse Vaginal septum with functioning uterus
– Isolated Vaginal agenesis with functioning uterus
– Isolated Cervical agenesis with functioning uterus
– Intermittent abdominal pain
– Possible difficulty with micturition
– Possible lower abdominal swelling
– Bulging bluish mebrane at the introitus or absent vagina (only dimple)
Imperforate hymen
Once Pregnancy and cryptomenorrhea are excluded:
The patient is a bioassy for Endocrine abnormalities
Four categoris of patients are indentified
1. Amenorrhea with absent or poor secondary sex Characters
2. Amenorrhea with normal 2ry sex characters
3. Amenorrhea with signs of androgen excess
4. Amenorrhea with absent uterus and vagina
AMENORRHEA
Absent or poor secondary sex Characteristiscs
AMENORRHEA
Normal secondary sex characteristics
Normal FSH, LH; -ve bleeding
history is suggestive of amenorrhea trumatica
Asherman's syndrome
• History of pregnancy associated D&C
• Rarely after CS, myomectocy T.B endometritis, bilharzia
• Diagnosis: HSG or hysterescopy
• Treatment : lysis of adhesions; D&C or hysterescopy + estrogen therapy (? ICUD or catheter)
Some will prescribe a cycle of Estrogen and Progesterone challenge Before HSG or Hysterescopy
Gonadal dysgenesis
• Chromosomally incompetent
– Classic turner's syndrome (45X0)
– Turner variants (45XO/46XX), (46X-abnormal X)
– Mixed gonadal dygenesis (45X0/46XY)
• Chromosomally competent
– 46XX (Pure gonadal dysgenesis)
– 46XY (Swyer's syndrome)
Turner's syndrome
• Sexual infantilism and short stature.
• Associated abnormalities, webbed neck, coarctation of the aorta, high-arched pallate, cubitus valgus, broad shield-like chest with wildely spaced nipples, low hairline on the neck, short metacarpal bones and renal anomalies
• High FSH and LH levels.
• Bilateral streaked gonads.
• Karotype - 80% 45, X0
- 20% mosaic forms (46XX/45X0)
• Treatment: HRT
None-dysgenesis ovarian failure
• Steroidogenic enzyme defects (17-hydroxylase)
• Ovarian resistance syndrome
• Autoimmune oophoritis
• Postinfection (eg. Mumps)
• Postoopherectomy
• Postradiation
• Postchemotherapy
Premature ovarian failure
• Serum estradiol < 50 pg/ml and FSH > 40 IU/ml on repeated occasions
• 10% of secondary amenorrhea
• Few cases reported, where high does estrogen or HMG therapy resulted in ovulation
• Sometimes immunotherapy may reverse autoimmune ovarian failure
• Rarely → spont. ovulation (resistant ovaries)
• Treatment : HRT (osteroporosis, atherogenesis)
Polycystic ovary syndrome
• The most common cause of chronic anovulation
• Hyperadrogenism; ↑ LH/FSH ratio
• Insulin resistance is a major biochemical feature (↑ blood insulin level → hyperandrogenism)
• Long term risks: Obesity, hirsutism, infertility, type 2 diabetes, dyslipidema, cardiovascular risks, endometrial hyperplassia and cancer
• Treatment depends on the needs of the patient and preventing long term health problems
Hypogonadotropic Hypognadism
• Normal height
• Normal external and internal genital organs (infantile)
• Low FSH and LH
• MRI to R/O intra-cranial pathology.
• 30-40% anosmia (kallmann's syndrome)
• Sometimes → constitutional delaly
• Treat according to the cause (HRT), potentially fertile
.
Constitutional pubertal delay
• Common cause (20%)
• Under statuer and delayed bone age (X-ray Wrist joint)
• Positive family history
• Diagnosis by exclusion and follow up
• Prognosis is good (late developer)
• No drug therapy is required- Reasurrance (?HRT)
Sheehan's syndrome
• Pituitary inablility to secrete gonadotropins
• Pituitary necrosis following massive obstetric hemorrhage is most common cause in women
• Diagnosis : History and ↓ E2, FSH, LH + other pituitary deficiencies (MPS test)
• Treatment: Replacement of deficient hormones
Weight-related amenorrhea
Anorexia Nervosa
• 1 ° or 2 ° Amenorrhea is often first sign
• A body mass index (BMI) < 17 kg/m2 → mentrual irregularity and amenorrhea
• Hypothalamic suppression
• Abnormal body image, intense fear of weight gain, often strenuous exercise
• Mean age onset 13-14 years (range 10-21 years)
• Low estradiol → risk of osteoporosis
• Bulemics less commonly have amenorrhea due to fluctuations in body weight, but any disordered eating pattern (crash diets) can cause mentrual irregularity.
• Treatment : ↑ body weight Psychiatrist referral)
Exercise-associated amenorrhoea
• Common in women who participate in sports (e.g. competitive athletes, ballet dancers)
• Eating disorders have a higher prevalance in female athletes than non-atheletes
• Hypothalamic disorder caused by abnormal gonadotrophin-releasing hormone pulsatility, resulting in impaired gonadotrophin levels, particulary LH, and subsequently low oestrogen levels
Contraception related amenorrhea
• Post-pill amenorrhea is not an entity
• Depot medroxyprogesterone acetate
Up to 80% of women will have amenorrhea after 1 year of use. It is reversible (oestrogen deficiency)
• A minoriy of women taking the progestogen-only pill may have reversible long term amenorrhoea due to complete suppression of ovulation
Late onset congenital adrenal hyperplasia
• Autosomal recessive trait
• Most common form is due to 21-hydroxylase deficiency
• Mild forms closely resemble PCO
• Severe forms show Signs of severe androgen excess
• High 17-OH-progesterone blood level
• Treatment : cortisol replacement and ? Corrective surgery
Cushings syndrome
• Clinical suspicion: Hirsutism, truncal obesity, purple striae, ↑ BP
• If suspicion is high: dexamethasone suppression test (1 mg PO 11 pm) and obtain serum cortisol level at 8 am: < 5 µg/dl excludes cushing's
• 24 hours to total urine free cortisol level to confirm diagnosis
• 2 forms; adrenal tumor or ACTH hypersecretion (pituitary or ectopic site)
Utero-vaginal Agenisis
Mayer-Rokitansky-Kuster-Hauser syndrome
• 15% of 1ry amenorrhea
• Normal breasts and sexual hair development & normal female looking genitalia
• Normal female range testoterone level
• Absent uterus and upper vagina & normal ovaries
• Karotype 46-XX
• 1530% renal, skeletal and middle eear anomalies
• Treatment: STERILE ? Vaginal creation (Dilation VS Vaginoplasty)
Adrogen insensitivity
Testicular feminization syndrome
• X-linked trait
• Absent cytosol receptors
• Normal breast but no sexual hair
• Normal looking femal external genitalia
• Absent uterus and upper vaginal
• Karotype 46, XY
• Male range testosterone level
• Treatment : gonadectomy after puberty + HRT
• ? Vaginal creation (dilation VS Vaginoplasty)
General Principles of management of Amenorrhea
• Attempts to restore ovulatory function
• If this is not possible HRT (oestrogen and progesterone) is given to hypo-estrogenic amnenorrheic women (to prevent osteoporosis; atherogenesis)
• Periodic progestogen should be taken by euestrogenic amenorrheic women (to avoid endometrial cancer)
• If Y chromosome is present gonadectomy is indicated
• Many cases require frequent re-evaluation
Hormonal treatment
Primary Amenorrhea with absent secondary sexual characteristics
To achieve pubertal development
Premarin 5mg D1-D25 + provera 10mg D15-D25 X 3 months; ↓ 2.5mg premarin X 3 months and ↓ 1.25mg premarin X 3 months
Maintenance therapy
0.625mg premaring + provera OR ready HRT preparation OR 30µg oral contraceptive pill
Summary
• Although the work-up of amenorrhea may seem to be complex, a carefully conducted physical examination with the history, and Looking to the patient as a bioassay for endocrin abnormalities, should permit the clinician to narrow the diagnostic possiblities and an accurate diagnosis can be obtained quickly.
• Management aims at restoring ovulatory cycles if possible, replacing estrogen when deficient and Progestorgengen to protect endometrium from unopposed estrogen.
• Frequent re-evalutation and reassurance of the patient.
THANK YOU FOR YOUR ATTENTION
Dr. Jehad Yousef
F.I.C.S., F.R.C.O.G
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
Shared genetics found between anti-Müllerian hormone and age at menopause
December 4th 2024In a recent study, an inverse relationship was discovered between anti-Müllerian hormone levels and early menopause, highlighting the need to develop interventions for fertility preservation based on genetics.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More